Varsha Bangalee

Department of Pharmaceutical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa


  • Research Article   
    Dolutegravir Reported Adverse Drug Reactions: A Systematic Review Protocol
    Author(s): Lesley Wadesango42471*, Ebenezer Wiafe42472, Kofi Boamah Mensah42473, Varsha Bangalee42474 and Neelaveni Padayachee42475

    Background: Until recently, the first-line regimen for the management of Human Immunodeficiency Virus (HIV) was Tenofovir (TDF)-Emtricitabine (FTC) and Efavirenz (EFV). However, the use of EFV has now been limited due to adverse neurosensory effects and a low genetic barrier to resistance. This regimen has been replaced by the Dolutegravir (DTG)-based regimen since DTG has a high genetic barrier to resistance. Studies have reported a higher risk of Immune Reconstitution Inflammatory Syndrome (IRIS), weight gain, insomnia, and neural tube defects amongst people who received DTG. This review aims to assess the Adverse Drug Reaction (ADR) profile of Dolutegravir by identifying and classifying Dolutegravir-associated adverse drug reactions. Methods: Studies will be identified from an electronic database search. Studies that are potentially eligi.. Read More»
    DOI: 10.31858/0975-8453.13.9.635-638

    Abstract HTML PDF